Dana Flanders
Stock Analyst at Guggenheim
(n/a)
# 4,352
Out of 4,711 analysts
8
Total ratings
n/a
Success rate
-30.13%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Dana Flanders
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| SCYX SCYNEXIS | Initiates: Buy | $25 | $1.00 | +2,400.25% | 1 | Jan 22, 2021 | |
| PCRX Pacira BioSciences | Initiates: Neutral | n/a | $18.98 | - | 1 | May 27, 2020 | |
| HRTX Heron Therapeutics | Initiates: Buy | $24 | $1.58 | +1,418.99% | 1 | May 27, 2020 | |
| COLL Collegium Pharmaceutical | Initiates: Neutral | n/a | $29.70 | - | 1 | May 27, 2020 | |
| LGND Ligand Pharmaceuticals | Initiates: Neutral | n/a | $114.64 | - | 2 | Mar 10, 2020 | |
| EBS Emergent BioSolutions | Upgrades: Buy | $60 → $75 | $8.10 | +825.93% | 2 | Nov 2, 2018 |
SCYNEXIS
Jan 22, 2021
Initiates: Buy
Price Target: $25
Current: $1.00
Upside: +2,400.25%
Pacira BioSciences
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $18.98
Upside: -
Heron Therapeutics
May 27, 2020
Initiates: Buy
Price Target: $24
Current: $1.58
Upside: +1,418.99%
Collegium Pharmaceutical
May 27, 2020
Initiates: Neutral
Price Target: n/a
Current: $29.70
Upside: -
Ligand Pharmaceuticals
Mar 10, 2020
Initiates: Neutral
Price Target: n/a
Current: $114.64
Upside: -
Emergent BioSolutions
Nov 2, 2018
Upgrades: Buy
Price Target: $60 → $75
Current: $8.10
Upside: +825.93%